Improvements in acne and skin oiliness with tazarotene 0.045% lotion in patients with oily skin. (31st December 2023)
- Record Type:
- Journal Article
- Title:
- Improvements in acne and skin oiliness with tazarotene 0.045% lotion in patients with oily skin. (31st December 2023)
- Main Title:
- Improvements in acne and skin oiliness with tazarotene 0.045% lotion in patients with oily skin
- Authors:
- Tanghetti, Emil A.
Zeichner, Joshua A.
Gold, Michael
Sadick, Neil
Cook-Bolden, Fran E.
Kircik, Leon H.
Stein Gold, Linda
Weiss, Jonathan
Tyring, Stephen K.
Del Rosso, James Q.
Guenin, Eric - Abstract:
- Abstract: Background: Excessive sebum production is a factor in acne development. Tazarotene 0.045% lotion has demonstrated reductions in acne lesions and acne-induced sequelae. Objective: Evaluate efficacy, changes in skin oiliness, and safety with tazarotene 0.045% lotion in participants with moderate-to-severe acne and oily skin. Methods: In two phase 3, double-blind, 12-week studies (NCT03168321; NCT03168334), participants aged ≥ 9 years with moderate-to-severe acne were randomized 1:1 to once-daily tazarotene 0.045% lotion or vehicle lotion ( N = 1614). This pooled, post hoc analysis included only participants self-categorized with oily skin at baseline on the Acne-Specific Quality of Life questionnaire item 19 (scores: 0 [extremely oily] to 6 [not at all oily]). Inflammatory/noninflammatory lesion counts, treatment success, skin oiliness, treatment-emergent adverse events (TEAEs), and cutaneous safety/tolerability were evaluated. Results: In all participants with oily skin ( n = 793), tazarotene provided greater reductions in inflammatory/noninflammatory lesions ( p < 0.001, both) and greater treatment success rates versus vehicle ( p < 0.01) at week 12. Over two-thirds of polymeric lotion-treated participants had subjective skin oiliness reductions by week 12, with around a third reporting 'low/not' oily skin. Tazarotene TEAE rates were similar to the overall population. Conclusions: Once-daily treatment with tazarotene 0.045% polymeric emulsion lotion may helpAbstract: Background: Excessive sebum production is a factor in acne development. Tazarotene 0.045% lotion has demonstrated reductions in acne lesions and acne-induced sequelae. Objective: Evaluate efficacy, changes in skin oiliness, and safety with tazarotene 0.045% lotion in participants with moderate-to-severe acne and oily skin. Methods: In two phase 3, double-blind, 12-week studies (NCT03168321; NCT03168334), participants aged ≥ 9 years with moderate-to-severe acne were randomized 1:1 to once-daily tazarotene 0.045% lotion or vehicle lotion ( N = 1614). This pooled, post hoc analysis included only participants self-categorized with oily skin at baseline on the Acne-Specific Quality of Life questionnaire item 19 (scores: 0 [extremely oily] to 6 [not at all oily]). Inflammatory/noninflammatory lesion counts, treatment success, skin oiliness, treatment-emergent adverse events (TEAEs), and cutaneous safety/tolerability were evaluated. Results: In all participants with oily skin ( n = 793), tazarotene provided greater reductions in inflammatory/noninflammatory lesions ( p < 0.001, both) and greater treatment success rates versus vehicle ( p < 0.01) at week 12. Over two-thirds of polymeric lotion-treated participants had subjective skin oiliness reductions by week 12, with around a third reporting 'low/not' oily skin. Tazarotene TEAE rates were similar to the overall population. Conclusions: Once-daily treatment with tazarotene 0.045% polymeric emulsion lotion may help improve patient-perceived skin oiliness in those with moderate-to-severe acne. … (more)
- Is Part Of:
- Journal of dermatological treatment. Volume 34:Number 1(2023)
- Journal:
- Journal of dermatological treatment
- Issue:
- Volume 34:Number 1(2023)
- Issue Display:
- Volume 34, Issue 1 (2023)
- Year:
- 2023
- Volume:
- 34
- Issue:
- 1
- Issue Sort Value:
- 2023-0034-0001-0000
- Page Start:
- Page End:
- Publication Date:
- 2023-12-31
- Subjects:
- Tazarotene -- retinoid -- acne -- skin oiliness
Skin -- Diseases -- Treatment -- Periodicals
Skin Diseases -- drug therapy -- Periodicals
Skin Diseases -- therapy -- Periodicals
616.5 - Journal URLs:
- http://informahealthcare.com/loi/jdt ↗
http://informahealthcare.com ↗ - DOI:
- 10.1080/09546634.2022.2147391 ↗
- Languages:
- English
- ISSNs:
- 0954-6634
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4968.767000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 25157.xml